For over 15 years, our team specializes in helping clients build comprehensive and competitive portfolios that align with their strategic goals, financial objectives, and manufacturing capabilities. We work to strengthen our clients' competitive position across various areas, including APIs, Finished Dosage Forms (FDFs), Value-Added Medicines (VAMs) in Europe, and 505(b)(2) products in the US, ensuring their portfolios are positioned for success in a dynamic and evolving industry.

At Annion, we provide comprehensive competitive market intelligence to help pharmaceutical companies stay ahead in a dynamic industry. Our tailored insights support strategic decision-making, optimize product pipelines, and enhance revenue growth. By closely monitoring market trends and competitors, we identify challenges and opportunities, empowering businesses to make informed decisions for long-term success.

Annion Pharma offers a broad range of consulting services, specializing in comprehensive risk assessments, toxicological reports, and substance categorizations, all delivered with a collaborative, client-centered approach. Our process begins with meticulous database and literature analysis, followed by mechanistic evaluations, read-across studies, and (Q)SAR investigations. Through critical thinking and in-depth analysis, we provide intelligent conclusions that ensure precise evaluations across a wide spectrum of substances.

Offering comprehensive evaluations for occupational risk assessments. Our expertise spans the analysis of a wide range of molecules to assess toxicity potential and deliver tailored reports, including Occupational Exposure Banding (OEB), Occupational Exposure Limits (OEL), and Occupational Toxicological Categorization for APIs, intermediates, and other substances. We ensure robust operational safety and toxicology support to meet the highest industry standards.